Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Download in electronic PDF format for $75
Abstract: Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment) for the topical treatment of leishmania major. Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain. This article represents part 3 of a 3-part article on the topic of cutaneous leishmaniasis. Part 1 discussed the treatment option of amphotericin-B liposomal gel, part 2 discussed the treatment option of paromomycin sulfate liposomal gel, and this final part (3) discusses the treatment option of photodynamic therapy.
Related Keywords:
cutaneous leishmaniasis, leishmania major, leishmania tropica, Israel, topical preparations, photodynamic therapy, daylight activation, photosensitizer, 5-aminolevulinic acid hydrochloride, formulations, amphotericin B liposomal gel, paromomycin sulfate liposomal gel
Related Categories:
DERMATOLOGY, EXCIPIENTS, FORMULATIONS, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
|
Sep/Oct 2019
Pg. 366-375
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
|
Jul/Aug 2019
Pg. 288-293
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
|
May/Jun 2019
Pg. 200-207
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
PostScription: Compounding in Israel
Zur Eyal
|
May/Jun 2009
Pg. 262-263
|
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
|
Nov/Dec 2018
Pg. 446-454
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Acidifying Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 1999
Pg. 309-310
|
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
|
Nov/Dec 2011
Pg. 458-463
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
|
Jan/Feb 2019
Pg. 23-31
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Current Topical Treatments in Wound Healing - Part 2
Helmke Christopher D
|
Sep/Oct 2004
Pg. 354-357
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
|
Mar/Apr 2019
Pg. 94-104
|
A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
|
Nov/Dec 2022
Pg. 480-488
|
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Israel Alan
|
May/Jun 2003
Pg. 176-178
|
Ascorbic acid 5% Topical Microemulsion
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 423
|
Trichloroacetic Acid 20%, Salicylic Acid 20%, Lactic Acid 10% in Flexible Collodion
Allen Loyd V Jr
|
Sep/Oct 2015
Pg. 410
|
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Allen Loyd V Jr
|
May/Jun 2015
Pg. 243
|
Return to Top |